Carbon nanotubes as VEGF carriers to improve the early vascularization of porcine small intestinal submucosa in abdominal wall defect repair
Received 3 December 2013
Accepted for publication 22 January 2014
Published 10 March 2014 Volume 2014:9(1) Pages 1275—1286
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Zhengni Liu,1,* Xueyi Feng,2,* Huichun Wang,1 Jun Ma,1 Wei Liu,3 Daxiang Cui,4 Yan Gu,1 Rui Tang,1
1Department of General Surgery, Shanghai Ninth People’s Hospital, Hernia and Abdominal Wall Disease Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of General Surgery, Lu’an People’s Hospital, Lu’an Affiliated Hospital of Anhui Medical University, Lu’an, Province Anhui, People’s Republic of China; 3Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Tissue Engineering, Shanghai, People’s Republic of China; 4Institute of Nano Biomedicine and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Research Institute of Micro/Nano Science and Technology, Bio-X Center, Shanghai Jiao Tong University, Shanghai, People's Republic of China
*These authors contributed equally to this work
Abstract: Insufficient early vascularization in biological meshes, resulting in limited host tissue incorporation, is thought to be the primary cause for the failure of abdominal wall defect repair after implantation. The sustained release of exogenous angiogenic factors from a biocompatible nanomaterial might be a way to overcome this limitation. In the study reported here, multiwalled carbon nanotubes (MWNT) were functionalized by plasma polymerization to deliver vascular endothelial growth factor165 (VEGF165). The novel VEGF165-controlled released system was incorporated into porcine small intestinal submucosa (PSIS) to construct a composite scaffold. Scaffolds incorporating varying amounts of VEGF165-loaded functionalized MWNT were characterized in vitro. At 5 weight percent MWNT, the scaffolds exhibited optimal properties and were implanted in rats to repair abdominal wall defects. PSIS scaffolds incorporating VEGF165-loaded MWNT (VEGF–MWNT–PSIS) contributed to early vascularization from 2–12 weeks postimplantation and obtained more effective collagen deposition and exhibited improved tensile strength at 24 weeks postimplantation compared to PSIS or PSIS scaffolds, incorporating MWNT without VEGF165 loading (MWNT–PSIS).
Keywords: vascular endothelial growth factor165, controlled release, multi-walled carbon nanotube, early vascularization
Synthetic or biological materials have been used to repair the abdominal wall defects caused by the extensive surgical tumor resections or the loss of large amounts of tissue following traumatic injury.1 The use of synthetic materials, including polypropylene, to repair such defects gives rise to the deposition of nonspecific fibrotic tissue, thereby leading to complications, such as bowel obstruction.2–4 On the other hand, biological materials lead to the regeneration of new site-specific tissue that is similar to the original host tissue in terms of histology and function.5 This is known as tissue endogenous regeneration. Therefore, biological materials are considered ideal implants for repairing abdominal wall defects.
As a widely used biological material, porcine small intestinal submucosa (PSIS) is prepared from the original material by removing all cells and retaining the three-dimensional extracellular matrix. The extracellular matrix acts as a scaffold onto which cells migrate and proliferate after an attachment to the substratum. The tensile strength of a hernia repair using PSIS is achieved via host tissue incorporation.6,7 However, the lack of early vascularization limits host tissue incorporation following implantation, weakening the mechanical strength of the defect site,8 and leading to implant failure.9,10 Delivery of exogenous angiogenic factors – such as VEGF – might facilitate early vascularization and promote efficient host integration.
VEGF is a potent angiogenic factor that is rapidly degraded due to its short half-life.11 Therefore, VEGF encapsulated in microspheres or nanospheres that undergo gel–sol transition are used for its delivery. However, encapsulated VEGF is often uncontrollably released from the carrier matrix.12,13 Using fibrin matrices, Wilcke et al14 developed a delayed-release system for the delivery of VEGF165 and basic fibroblast growth factor to repair full-skin defects on the backs of mice. After the first 48 hours, the concentration of VEGF165 released decreased by 50% compared to that in the first 24 hours. Such rapid releasing might be prevented by the binding of the growth factors to biodegradable polymeric matrices. Then, the sustained releasing of the growth factors will be obtained under the control of locally biodegradable polymeric matrices.15 However, owing to its biodegradable and polyporous characteristics, achieving the controlled release of VEGF from PSIS remains a challenge. Abdominal wall defect repair requires the sustained release of VEGF at high concentrations to ensure early vascularization.
The development of nanomaterials has allowed the controlled delivery of therapeutic peptides. Using multiwalled carbon nanotubes (MWNT), we designed a system for the controlled release of therapeutic molecules to achieve early vascularization. We chose MWNT because of its hollow and cylindrical structure that could readily carry and deliver drug molecules (for example, amphotericin B or methotrexate).16 Besides that, plasma polymerization is an effective method for nanotube functionalization on the surface of substrates with a polymer coating.17 In this study, MWNT were prepared through plasma polymerization to carry and release VEGF165 which makes it possible to deposit the uniform poly(lactic-co-glycolic) acid (PLGA) coating on MWNT firmly and steadily. Furthermore, owing to the hollow and cylindrical structure with the wide contact surface of MWNT, VEGF can be not only loaded into the tube, but it can be adhered on the sidewall of MWNT with noncovalent integration. Hence, the structure and the coating-relevant plasma polymerization of VEGF–MWNT that we developed makes the system totally different from the PLGA–VEGF microsphere.
We hypothesized that VEGF165 could be released from the hollow tube structures of MWNT during the slow degradation of the PLGA used to coat the material, thereby avoiding the uncontrolled burst release of growth factor from the carrier matrix, such as PLGA–VEGF microsphere, and supporting prolonged and sustained release. Such a system could then support early neovascularization, leading to better tissue regeneration.
Consequently, we constructed a composite scaffold with an optimal content of VEGF165–MWNT that was capable of carrying and releasing VEGF165 without inhibiting cell proliferation (Figure 1A). Such composite scaffolds were implanted into the abdominal wall defect sites in rats to evaluate their efficacy in inducing early neovascularization.
All experiments were conducted according to local guidelines on the ethical use of animals and the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (US National Institutes of Health publication number 85–23, revised 1996). Animal study protocols were approved by an institutional review committee at the Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China.
The versatile features of MWNT are functionalized, such as the multipurpose innovative carriers for drug delivery and diagnostic applications via physicochemical treatment. In our study, it means the MWNT are purified and treated by plasma polymerization to obtain the ability to carry and release VEGF165. Raw MWNT (Wako Pure Chemical Industries, Ltd, Osaka, Japan) was purchased and purified as previously reported.18 VEGF165 was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Recombinant human VEGF165 was loaded into purified MWNT at a ratio of 1:10,000 (0.1 μg:1 mg) by solution sonication for 30 minutes. The suspensions were then freeze-dried for 48 hours. The VEGF165-loaded MWNT were coated with PLGA film by plasma polymerization to prepare the VEGF165-releasing device, as reported previously.19 The ratio of lactic acid to glycolic acid was 1:2. After plasma polymerization for 12 hours, the novel MWNT were characterized using high-resolution transmission electron microscopy (HRTEM). The amount of VEGF165 loaded into MWNT was analyzed by human VEGF enzyme-linked immunosorbent assay (ELISA) kits (Quantikine® Colorimetric Sandwich ELISAs, R&D Systems), according to the manufacturer’s instructions.
The PSIS scaffolds were prepared as previously described.20 In brief, fresh porcine small intestine was obtained from Fuxin abattoir (Shanghai, People’s Republic of China). After flushing the intestinal contents, the serosal and muscular layers of the porcine small intestine were removed mechanically. Then, the decellularized treatment was done by shaking the small intestinal segments at 4°C in 1 L of 0.2% Triton X-100 (Sigma-Aldrich, St Louis, MO, USA) containing 26.5 mmol/L ammonium hydroxide for 7 days. The two-layer PSIS grafts were trimmed into a size of 40×30×0.2 mm membranes.
Afterward, the VEGF165-releasing devices were suspended in 2 mL distilled water by ultrasonication to prepare the suspensions. Varying amounts of the suspension were integrated with the two-layer PSIS scaffold by dipping and sonication. Then, the VEGF165–MWNT contained composite scaffolds were freeze-dried. The structures of prepared PSIS scaffolds and composite scaffolds including VEGF165–MWNT were observed by scanning electron micrography (SEM Ultra55, Carl Zeiss AG, Oberkochen, Germany). Scaffolds were then trimmed to a size of 40×30×0.2 mm and stored at −80°C.
Evaluation of in vitro properties of composite scaffolds
Group A, group B, group C, and group D, containing 1%, 3%, 5%, and 10% weight (mg per mg) of VEGF165–MWNT in the composite scaffolds, were assigned as four experimental groups. The PSIS scaffold without VEGF165–MWNT was assigned as the control group. The optimal content of VEGF165–MWNT was determined by analyzing VEGF release, bioactive property, biocompatibility, and the mechanical property of the composite scaffold.
Examination of controlled release and bioactive property of VEGF165
To assess the amount of VEGF165 released, we incubated 50 mg of composite scaffolds from each group in 50 mL phosphate buffered saline at 37°C with occasional shaking (120 revolutions per minute). Then, 100 μL aliquots of the incubation buffers were taken at 10 time points: 1 hour; 6 hours; 12 hours; and at 1 day; 2 days; 3 days; 4 days; 5 days; 6 days; and 7 days. The samples were analyzed by human VEGF–ELISA kits. The cumulative amounts of released VEGF165 were plotted against time to exhibit the in vitro VEGF165-releasing concentration.
The bioactivity of released VEGF165 was assessed by endothelial cell proliferation assay. In this test, the PSIS and composite scaffolds were cultured with 10 mL of medium M 199 containing 10% fetal bovine serum for 3 days to release the loaded VEGF165 sufficiently, and the leaching solutions were collected. In the next step, 100 μL of human umbilical vein endothelial cell (HUVECs) (American Type Culture Collection [ATCC], Manassas, VA, USA) suspension in HUVEC growth medium (PromoCell GmbH, Heidelberg, Germany) was seeded onto individual wells of 96-well plates at a density of 2×103 cells per mL. Cultures were maintained under standard conditions for adherence. Following this, the culture medium was replaced with 100 μL leaching solution. HUVECs cultured with PSIS scaffold leaching solution were assigned as the control group, while the HUVECs cultured with composite scaffolds leaching solution were assigned as the experimental groups. HUVECs were cultured serially and counted at 1 day, 3 days, 5 days, and 7 days without changing medium, using Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan), following manufacturer’s instructions.
Examination of biocompatibility
Biocompatibility of the composite scaffold was determined by the fibroblasts’ proliferation test. The fibroblasts were cocultured with PSIS scaffold as the negative control. Fibroblasts cultured in MWNT suspensions (1 mg/mL) were used as positive control. The fibroblast cell counting test was similar to that described for HUVECs.
Examination of mechanical properties
Mechanical properties of the 50×10 mm samples were examined at room temperature using a uniaxial materials testing machine (Model 5542; Instron, Norwood, MA, USA), as described previously.20 The abdominal wall strengths in rats were also recorded.
Evaluation of in vivo properties of composite scaffold
In addition, 60 male Sprague Dawley rats (weight, 200–250 g) (SLAC National Rodent Laboratory Animal Resources, Shanghai, People’s Republic of China) were divided into three groups, according to the nature of the scaffold implanted. The PSIS and MWNT–PSIS groups were assigned as negative control groups, and the VEGF165–MWNT–PSIS group was assigned as the experimental group. Each group had 20 rats. The rats were housed in accordance with current national guidelines on animal welfare. The environment of cages was maintained at 18°C −26°C, with a relative humidity of 30%–70%.
Rats were anesthetized by intramuscular injection of ketamine at the dose of 60 mg/kg. The abdominal skin was shaved and disinfected with a povidone-iodine solution. A longitudinal midline abdominal incision of 50 mm length was made, and a complete defect – including fascia, muscles, and peritoneum – was created (with a 30×20 mm size). Subsequently, a sterile scaffold piece with dimensions of 40×30 mm was implanted into each rat to repair the defect in a sublay manner. Each layer of the defects was stitched up and overlapped with the edge of the scaffolds for 5 mm on each side. The scaffold was fixed with 3–0 polypropylene with interrupted sutures. Skin was closed with continuous sutures with 2–0 absorbable polydioxanone (Ethicon, Inc., Somerville, NJ, USA). Antibiotics were not administered during or after the implantation.
Daily examination included study of the animals’ eating, drinking, urination, and bowel movements, palpation of the implant sites for integrity, and visual inspection of the abdominal body wall for asymmetry or abnormal contours. Four rats from each group were randomly sacrificed in sequence at 1 week, 2 weeks, 4 weeks, 12 weeks, and 24 weeks postimplantation. Rats were suspended vertically and horizontally to assess the status of the repaired abdominal wall. The implants on the subcutaneous and visceral sides were examined for the presence of seromas, hematomas, and infection. The site dimensions were measured to assess possible intracorporeal shrinkage or expansion. An established grading scale, as described by Jenkins et al,21 was used to semiquantitatively grade adhesion tenacity (Table 1). The thickness of the implant was estimated by ten random measurements over the central part of the implant 24 weeks after implantation.
Table 1 Semiquantitative adhesion scoring system
The implants and a 1 cm strip of surrounding host tissue were resected. Sections of the explant were fixed with 10% formalin, paraffin embedded, and sectioned into 5 μm slices. Immunostaining was performed to examine neovascularization of the implants at various stages of regeneration. Samples were incubated with anti-von Willebrand factor antibody (vWF; 1:1,000; Abcam, Cambridge, MA, USA) to evaluate the density of capillary vessels. Sections on which immunohistochemistry was performed without primary antibody served as negative controls. The average percentage of areas with blood vessels (% Abv) was calculated for ten randomly selected fields (×400), using Image-Pro Plus software 6.0 (Media Cybernetics, Inc., Silver Spring, MD, USA), according to the following equation:
Qualitative assessment of collagen deposition was performed by using Masson’s trichrome stain. Hematoxylin and eosin staining was performed to quantify the presence of foreign body giant cells, polymorphonuclear cells and mononuclear cells. The scale used was similar to that described by Badylak et al (Table 2).22 Five fields per slice were counted under 400× magnification (E600; Nikon Corporation, Tokyo, Japan). One pathologist, who was blinded to the tested materials, performed all evaluations.
Table 2 Histologic scoring criteria for microscopic examination
Examination of mechanical properties
The load of 1 cm wide explants was measured by mechanical evaluation as described. The tensile strength of the explant was calculated from the stress–strain curves.
Kolmogorov–Smirnov tests were performed for ranked data. Measurement data were recorded as mean ± standard deviation. The differences in quantitative parameters between experimental and control groups were analyzed by one-way analysis of variance followed by the Bonferroni post hoc test. SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. P<0.05 was considered as statistically significant.
The transmission electron microscopy examination showed that acid treatment improved the reunion and winding phenomenon in raw MWNT (Figure 1B). After VEGF165 loading, the surface functionalization of MWNT was achieved by depositing PLGA film onto the nanotubes by plasma polymerization. The microstructure of the composites was characterized using HRTEM (Figure 1C–E). The results of ELISA showed that the VEGF165 loading efficiency was 15.1%±0.6%.
Evaluation of properties of composite scaffold in vitro
The composite scaffolds were divided into four experimental groups, according to the VEGF165–MWNT content, to assess the VEGF165 releasing and bioactive properties, mechanical properties, and biocompatibility in vitro.
Examination of released amount and bioactive property of VEGF165
The cumulative release of VEGF165 in four experimental and one control groups is shown in Figure 2A. In groups A and B, the cumulative concentration of VEGF165 released after 7 days was 143.2±5.26 pg/mL and 179.8±1.37 pg/mL, respectively. This demonstrated that 94.8%±3.2% and 40.7%±4.3% of the loaded amount of VEGF165 had been released from the two groups during the course of the experiment.
The corresponding values in groups C and D were 377.44±6.10 pg/mL and 460.33±6.01 pg/mL, respectively, which demonstrated that 50.0%±4.1% and 30.5%±3.5% of the loaded amount of VEGF165 had been released during the experiment. The concentration of VEGF165 released during the first 6 hours in group A was low. Its concentration exceeded that in the control group from the next time point (P<0.05). In other experimental groups, the VEGF165 released was significantly higher than that in the control group over 7 days (P<0.05). The VEGF165 concentration in the composite scaffolds increased significantly when VEGF165-releasing devices were used (P<0.05). Accordingly, group D, which incorporated 10 weight percent VEGF165-releasing devices, released the highest amount of VEGF165 in vitro (P<0.05).
Proliferation of HUVECs in response to the scaffold-derived VEGF165 is shown in Figure 2B. Although group D released the highest concentration of VEGF165, it was found to inhibit HUVEC proliferation (P<0.05). The proliferation of HUVECs in group B and group C increased by 1.6-fold and 2.6-fold, respectively, compared to that of the control group after 7 days of culture (P<0.05). These results indicated that the scaffold containing 5 weight percent VEGF165-releasing devices had optimum ability to stimulate the proliferation of HUVECs in vitro.
Examination of biocompatibility
Fibroblast proliferation in group A, group B, and group C was not significantly different from that observed in the control group (P>0.05), suggesting that these groups had appropriate scaffolds and good biocompatibility. In contrast, the fibroblast proliferation in group D was significantly slow and inhibited eventually (P<0.05; Figure 2C).
Examination of mechanical properties
The tensile strength of various composite scaffolds is shown in Figure 2D. The results indicated that the tensile strength of the composites did not linearly increase with the increasing of MWNT.
Scaffold containing 5 weight percent of VEGF165–MWNT exhibited optimal properties in vitro. Therefore, this scaffold was used as the experimental group (VEGF–MWNT–PSIS) for later in vivo studies. The composite scaffold containing the same concentration of MWNT without VEGF165 (MWNT–PSIS) and the PSIS scaffold served as control groups.
Evaluation of composite scaffold in vivo
Rats implanted with scaffolds (Figure 3A–C) showed postoperative recovery from surgery and survived until sacrificed. There were no clinical signs of surgical site infection in any groups. Examination of explant revealed no herniation around or at the repaired site. Two weeks after surgery, seroma was observed in one rat belonging to the PSIS group and another in the MWNT–PSIS group. Further examination showed evidence of host tissue rupture adjacent to the implanted interface in one animal belonging to the PSIS group 2 weeks after surgery. The rupture led to small intestinal obstructions in parts of the surgical sites.
White arrows in Figure 3D–F indicate the contraction or expansion of implants surrounded by sutures. In addition, 24 weeks after surgery, the surface area of the PSIS implants (10.22±0.82 cm2) diminished by 14.8%, while the surface area of MWNT–PSIS (16.32±1.32 cm2) and VEGF–MWNT–PSIS implants (17.90±1.56cm2) increased by 36% and 49%, respectively (P<0.05). There was no significant difference between the implant surface area of the MWNT–PSIS group and that of the VEGF–MWNT–PSIS group (P>0.05).
The composite implants displayed more extensive and dense adhesions between the implants and the peritoneal contents than the PSIS implants within the first 4 weeks. One week after implantation, the tenacity and the surface area of the adhesion scores in the VEGF–MWNT–PSIS group were nearly threefold of that in the PSIS group (P<0.05). However, the adhesions weakened dramatically and dropped to a level comparable to that of PSIS group at 12 weeks postimplantation (P>0.05). At 24 weeks postimplantation, adhesions were negligible. Adhesions were not significantly different between the two composite groups (MWNT–PSIS and VEGF–MWNT–PSIS) throughout the entire experimental periods (P>0.05; Figure 3G–K).
At 24 weeks postimplantation, all explants were thicker than the original scaffolds (0.20 mm; P<0.05). The thickness of explants in the composites groups (MWNT–PSIS =0.40±0.03 mm; VEGF-MWNT–PSIS =0.42±0.04 mm) was higher than that in the PSIS group (0.28±0.02 mm; P<0.05). There was no significant difference in the thickness of explants of the two composite groups (P>0.05).
Histological examination of host tissue incorporation
Host tissue incorporation, defined by new collagen deposition and new vessel growth into the implants,23 was determined for both experimental and control groups. Two weeks after implantation, the density of capillary ingrowth was significantly higher in VEGF–MWNT–PSIS (3.1%±1.1%) than that in PSIS (1.2%±0.3%) and MWNT–PSIS (0.7%±0.3%) (P<0.05). Neovascularization continued in the VEGF–MWNT–PSIS group until 12 weeks after implantation.
Afterward, similar density of vessels was observed inside the original scaffold implantation sites with no statistical difference among all groups at 24 weeks (P>0.05; Figure 4A–J). Masson’s trichrome staining revealed that the explants from the VEGF–MWNT–PSIS group induced more collagen deposition from 4–24 weeks than the other two groups (P<0.05), while there was no significant difference in collagen deposition between the PSIS and the MWNT–PSIS groups. All the explants showed similar collagen organization after implantation (P>0.05; Figure 5).
Examination of mechanical properties after implantation
All scaffolds in this study failed at the interface between the scaffold and the abdominal wall. Therefore, the reported values do not represent the strength of the actual material, but the integration process at the level of the interface with the surrounding tissue – termed the “strength of incorporation”.24,25 The strength of incorporation of all explants after implantation was significantly lower than that of initial scaffolds throughout the evaluation periods. These values decreased to a minimum (below that of the natural abdominal wall) after 2 weeks, and it gradually increased thereafter to a maximum at 24 weeks postimplantation. MWNT–PSIS and VEGF–MWNT–PSIS explants maintained considerably higher tensile strength within the initial 2 weeks compared to that of the PSIS explants (P<0.01). However, the difference between them was statistically insignificant (P>0.05). At later time points, the VEGF–MWNT–PSIS explants exhibited greater strength of incorporation than the other two groups (P<0.05). The MWNT–PSIS explants eventually exhibited a strength of incorporation comparable to that of PSIS explants (P>0.05; Figure 4K).
Microscopic examination revealed the presence of mixed infiltrating inflammatory cells after implantation (Figure 6). As evident from the scores of foreign body cells and polymorphonuclear cells at the interface, the MWNT–PSIS and the VEGF–MWNT–PSIS explants showed pronounced inflammatory responses, which were significantly greater than that in PSIS explants 1 week after implantation (P<0.05). The inflammatory responses were evident throughout the period of evaluation, with peak level observed at 2 weeks postimplantation in composite explants. Inflammatory responses dropped to negligible levels by the end of the study (P<0.05). The inflammatory response was not significantly different among the two composites explants (P>0.05).
When used in repairing abdominal wall defects, PSIS serves as a scaffold, providing mechanical support to initially counteract intra-abdominal pressure and promoting host tissue incorporation to compensate for the loss of mechanical strength with the degradation of implants during subsequent periods. However, the insufficient early vascularization in PSIS scaffolds following implantation leads to limited host tissue incorporation and may cause herniation and hernia recurrence in clinical study. The scaffold developed in this study supported sustained release of VEGF165, accelerated angiogenesis and neovascularization, and promoted effective host tissue incorporation.
Our study proved that due to their three-dimensional hollow core structure and PLGA-coating, functionalized MWNT can be used as carriers of VEGF165 to ensure its sustained release. VEGF165 was loaded in the tube and on the wall of MWNT, though the percentage distributed in each compartment was not clear. The HRTEM graphs confirmed that the MWNT were coated with PLGA. The plasma functionalization technique used in our study was similar to that described by Shi et al,17 who prepared PLGA-coated carbon nanotubes (CNT) as binders to carry paclitaxel. To our knowledge, this is the first time that plasma surface functionalization was used to construct a VEGF165-releasing device that was then used to repair abdominal wall defects. Our results demonstrated that the VEGF165 concentration in composite scaffolds was significantly higher than that in PSIS scaffolds over 7 days. The result indicates the scaffolds in group D obtained the highest cumulative released concentration and lowest released rate in all groups over 7 days. The reversed appearance in group D implies that the high concentration of VEGF165–MWNT impregnated retards the effective released manner. Apparently, the speculation can be supported by the tendency that – with the increase of VEGF–MWNT in the scaffold – the released rate of VEGF–MWNT decreased, while the cumulative released concentration of that increased in our study. With the concentration of separating VEGF–MWNT increased in scaffold, it caused the local aggregation of MWNT,26 and more VEGF–MWNT device was incorporated into the inner of the three-dimensional scaffold and released more slowly with scaffold degradation.
Our study showed that the VEGF165 released from VEGF–MWNT–PSIS led to a higher blood vessel density in the explant and an early-stage boost of neovascularization. However, the real-time concentrations of VEGF165 released in vivo from the implants were not determined. To the best of our knowledge, many imaging strategies capable of monitoring VEGF levels quantitatively have been reported.27,28 However, the absence of sophisticated methods in situ to monitor and distinguish the concentration of the unreleased VEGF from the released VEGF respectively may hinder the mechanistic investigations in the sustained release of the composite scaffold. Hence, more experimental data of labeled VEGF165 and MWNT released with degradation in vivo is required to provide a means for further understanding the released mechanism of the composite scaffold. In the present study, when compared with controls, a higher blood vessel density was observed in the VEGF–MWNT–PSIS explants during the 12 weeks of postimplantation. Compared to the PSIS and the MWNT–PSIS implants, early neovascularization of the VEGF–MWNT–PSIS implant stimulated more collagen production. This was further supported by the observation of well-vascularized and organized fibrous connective tissues in the VEGF–MWNT–PSIS explants.
The key factor for host tissue incorporation is early and stable neovascularization, which is critical for the delivery of oxygen and nutrients to actively regenerating tissues, and restores endothelial cell signaling.29 Further, the tensile strength of new fascia was reinforced from the regenerated tissue in response to collagen deposition.
Our study showed that early and thorough host tissue incorporation achieved using VEGF–MWNT–PSIS in vivo was the main source of tensile strength at the interface with the host tissues in the abdominal wall defects repair. Within the first 2 weeks of postoperation, implants containing MWNT exhibited greater strength of incorporation when compared to the PSIS implants, owing to the structure of the nanocomposite support. However, the tensile strength of all three groups reached a nadir 2 weeks following implantation when the implant had undergone only limited incorporation. Thus, the degradation rate of the implant outpaced the rate of collagen deposition and the replacement of fibrous connective tissue. The strength of incorporation of all the tested explants at this time point was below the values of natural abdominal wall in rats (2.26±0.43 MPa), although no hernia was observed.
However, the VEGF–MWNT–PSIS implant facilitated new vessel ingrowth and collagen deposition that reinforced the tensile strength starting from 4 weeks to the end of the study. The strength of incorporation of PSIS and MWNT–PSIS explants increased slightly, owing to the limited and persistent host tissue incorporation.
Although we successfully introduced the MWNT as carriers for the sustained release of VEGF165, some adverse effects were observed. First, the MWNT-containing implants caused pronounced inflammatory responses within the first 4 weeks after implantation. In contrast, PSIS implants only induced a mild inflammatory response. We believe that the enhanced inflammatory response induced more severe adhesion compared to PSIS implants. However, the inflammatory responses subsided with degradation, host tissue incorporation, and replacement of the implants at the repair site in all three groups. Moreover, PSIS is a natural and completely absorbable biomaterial, while MWNT are nonabsorbable and underwent rapid, first-order clearance from the blood compartment via renal excretion, although the CNT has been proved to have little influence on cell proliferation within safe concentration by various study.30–32 The interaction between MWNT and VEGF in our system is noncovalent, which is considered a favorable factor for efficient drug release. Our system is not perfect, but we deem it a meaningful attempt to improve the performance of natural biological material, and a more ideal carrier will be adapted to the sustained release system in the near future.
The preparation and use of functionalized MWNT-carrying VEGF165 led to accelerated tissue repair by ensuring sustained growth factor release. To our knowledge, this is the first time this novel VEGF165 delivery device was integrated with PSIS to construct a composite scaffold that improved neovascularization – thereby achieving enhanced host tissue remodeling and repair. Our results pave the way for the development of advanced materials for drug delivery and tissue regeneration.
The authors thank Daxiang Cui for technical support. This work was supported by the Medicine and Engineering Crossed Foundations, Shanghai Jiao Tong University (grant number YG2010MS50 and YG2013MS61).
The authors report no conflicts of interest in this work.
Eriksen JR, Gögenur I, Rosenberg J. Choice of mesh for laparoscopic ventral hernia repair. Hernia. 2007;11(6):481–492.
Leber GE, Garb JL, Alexander AI, Reed WP. Long-term complications associated with prosthetic repair of incisional hernias. Arch Surg. 1998;133(4):378–382.
Iannitti DA, Hope WW, Norton HJ, et al. Technique and outcomes of abdominal incisional hernia repair using a synthetic composite mesh: a report of 455 cases. J Am Coll Surg. 2008;206(1):83–88.
Mahmoud Uslu HY, Erkek AB, Cakmak A, et al. Incisional hernia treatment with polypropylene graft: results of 10 years. Hernia. 2006;10(5):380–384.
Vaught JD, Kropp BP, Sawyer BD, et al. Detrusor regeneration in the rat using porcine small intestinal submucosal grafts: functional innervation and receptor expression. J Urol. 1996;155(1):374–378.
Badylak S, Kokini K, Tullius B, Whitson B. Strength over time of a resorbable bioscaffold for body wall repair in a dog model. J Surg Res. 2001;99(2):282–287.
Ko R, Kazacos EA, Snyder S, Ernst DM, Lantz GC. Tensile strength comparison of small intestinal submucosa body wall repair. J Surg Res. 2006;135(1):9–17.
Poulose BK, Scholz S, Moore DE, et al. Physiologic properties of small intestine submucosa. J Surg Res. 2005;123(2):262–267.
Petter-Puchner AH, Fortelny RH, Walder N, et al. Small intestine submucosa (SIS) implants in experimental IPOM repair. J Surg Res. 2010;161(2):264–271.
Lai JY, Chang PY, Lin JN. Body wall repair using small intestinal submucosa seeded with cells. J Pediatr Surg. 2003;38(12):1752–1755.
Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev. 2012;64(7):640–665.
Shireman PK, Hampton B, Burgess WH, Greisler HP. Modulation of vascular cell growth kinetics by local cytokine delivery from fibrin glue suspensions. J Vasc Surg. 1999;29(5):852–861; discussion 862.
Ehrbar M, Djonov VG, Schnell C, et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res. 2004;94(8):1124–1132.
Wilcke I, Lohmeyer JA, Liu S, et al. VEGF(165) and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo. Langenbecks Arch Surg. 2007;392(3):305–314.
Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol. 2003;12(6):295–310.
Besteman K, Lee JO, Wiertz FGM, Heering HA, Dekker C. Enzyme-coated carbon nanotubes as single-molecule biosensors. Nano Lett. 2003;3(6):727–730.
Shi D, Guo Y, Dong Z, et al. Quantum-Dot-Activated Luminescent Carbon Nanotubes via a Nano Scale Surface Functionalization for in vivo Imaging. Adv Mater. 2007;19(22):4033–4037.
Liu J, Rinzler AG, Dai H, et al. Fullerene pipes. Science. 1998;280(5367):1253–1256.
Guo Y, Shi D, Cho H, et al. In vivo Imaging and Drug Storage by Quantum Dot Conjugated Carbon Nanotubes. Advanced Functional Materials. 2008;18(17):2489–2497.
Liu Z, Tang R, Zhou Z, Song Z, Wang H, Gu Y. Comparison of two porcine-derived materials for repairing abdominal wall defects in rats. PLoS One. 2011;6(5):e20520.
Jenkins SD, Klamer TW, Parteka JJ, Condon RE. A comparison of prosthetic materials used to repair abdominal wall defects. Surgery. 1983;94(2):392–398.
Badylak S, Kokini K, Tullius B, Simmons-Byrd A, Morff R. Morphologic study of small intestinal submucosa as a body wall repair device. J Surg Res. 2002;103(2):190–202.
MacLeod TM, Sarathchandra P, Williams G, Sanders R, Green CJ. Evaluation of a porcine origin acellular dermal matrix and small intestinal submucosa as dermal replacements in preventing secondary skin graft contraction. Burns. 2004;30(5):431–437.
Meyer T, Schwarz K, Ulrichs K, Höcht B. A new biocompatible material (Lyoplant) for the therapy of congenital abdominal wall defects: first experimental results in rats. Pediatr Surg Int. 2006;22(4):369–374.
Gaertner WB, Bonsack ME, Delaney JP. Experimental evaluation of four biologic prostheses for ventral hernia repair. J Gastrointest Surg. 2007;11(10):1275–1285.
Smart SK, Cassady AI, Lu GQ, Martin DJ. The biocompatibility of carbon nanotubes. Carbon. 2006;44(6):1034–1047.
Kang CM, Koo HJ, Lee KC, et al. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression. Biomaterials. 2013;34(28):6839–6845.
Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res. 2008;14(13):4146–4153.
Mondalek FG, Ashley RA, Roth CC, et al. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid-poly (lactide-co-glycolide) nanoparticles: from fabrication to preclinical validation. J Biomed Mater Res A. 2010;94(3):712–719.
Singh R, Pantarotto D, Lacerda L, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A. 2006;103(9):3357–3362.
Tian F, Cui D, Schwarz H, Estrada GG, Kobayashi H. Cytotoxicity of single-wall carbon nanotubes on human fibroblasts. Toxicol in Vitro. 2006;20(7):1202–1212.
Meng J, Song L, Meng J, et al. Using single-walled carbon nanotubes nonwoven films as scaffolds to enhance long-term cell proliferation in vitro. J Biomed Mater Res A. 2006;79(2):298–306.
© 2014 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.